中国的NMPA接受新的肾癌治疗申请,包括fruquintinib和sinpilimab。 China's NMPA accepts application for new kidney cancer treatment combining fruquintinib and sintilimab.

Hutchmed和Innovent宣布,中国的NMPA已接受他们的申请,在最初治疗失败后,接受新的fruquintinib和sintilimab综合疗法,治疗高级肾癌。 Hutchmed and Innovent announced that China's NMPA has accepted their application for a new combination therapy of fruquintinib and sintilimab to treat advanced kidney cancer after initial treatments fail. 在最近的一项研究中,治疗表明存活率和回复率有所改善,产生了可管理的副作用。 The therapy showed improvements in survival rates and response rates in a recent study, with manageable side effects. 这标志着 sintilimab的第10个迹象, 可以为中国的病人提供新的治疗选择。 This marks the 10th indication for sintilimab and could offer a new treatment option for patients in China.